Abstract
Chronic Eosinophilic Pneumonia (CEP) is a rare idiopathic eosinophilic
lung disease characterized by a triad of pulmonary symptoms,
radiographic findings and peripheral and/or lung eosinophilia. CEP is
usually treated with oral corticosteroids however, treatment durations
commonly exceed 12 months, relapses occur in ½ of patients and adverse
effects of steroid use are common. We report a case of an 11-year-old
female with corticosteroid refractory CEP who experienced clinical
remission after initiation of dupilumab, a monoclonal antibody therapy
approved for eosinophilic or steroid dependent asthma that inhibits IL-4
and IL-13. This case demonstrates the potential role of biologic agents
in CEP.